Skip to main content

Table 2 Analysis of cytokines in nasal lavages

From: Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold

 

first visit day 1

second visit day 3/4

second visit day 3/4

 
 

all

Iota-Carrageenan

Placebo

p-value

FGF-2

5.9 (5.9)

2.5 (2.8)

7.5 (5.6)

0.04

Fractalkine

87.0 (74.5)

46.4 (32.4)

79.7 (39.3)

0.023

GRO

252 (233)

156 (112)

339 (417)

n.s.

G-CSF

45.5 (89.1)

10.9 (17.9)

78.5 (186)

n.s.

IL-8

18.7 (30.6)

14.4 (10.8)

21.0 (22.4)

n.s.

IL-1α

35.3 (30.0)

28.8 (14.4)

43.1 (28.9)

n.s.

IP-10

1790 (3177)

970 (1769)

3016 (4033)

n.s.

IL-10

1.6 (4.22)

0 (0)

5.5 (13.6)

0.049

IL-1ra

164 (129)

174 (320)

131 (85)

n.s.

IFN-α2

11.6 (8.0)

8.7 (4.1)

11.5 (5.6)

n.s.

IL-12(p40)

10.6 (14.0)

9.1 (9.7)

8.0 (9.8)

n.s.

  1. Comparison of cytokine levels on day 1 and day 3/4. Shown are mean levels in pg/ml ± standard deviation. Lower quantification limit was 3.2 pg/ml, values below were set to '0'. P-values: comparison verum versus placebo by Mann-Whitney U-test.